Business
Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study
Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study.
About this update from Wellbeing Digital Sciences Inc.
[{"type":"text","content":"\n VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has been engaged by Lophos Pharmaceuticals Inc. (“Lophos”) to evaluate a path to market for sustainably grown, peyote-derived natural health products (“NHPs”). Lophos is a Canadian psychedelic research company focused on cultivation and drug development. Peyote has legal status in Canada, but mescaline – the drug derived from the plant – remains a Schedule 3 controlled substance. With a focus on NHPs, potential paths to market will be evaluated based on the safety and sanitary requirements, quality specifications for peyote-derived inputs, and permissible label claims for packaging and sales. Management Commentary “Lophos is currently exploring the potential benefits of a peyote-derived natural health product with the support of KGK Science. There are challenges to growing peyote, and the thirteen-year-long natural regrowth cycle is a major threat to the endangered plant. At Lophos, we are researching accelerated, responsible cultivation techniques for reducing the long growth cycle. The goal is to provide our partners with therapeutic peyote derivatives, grown in a sustainable manner that are beneficial to the plant itself, and respectful integrations of traditional medicinal plants,” said Claire Stawnyczy, Founder and CEO of Lophos. “We are very excited to engage with Lophos. Peyote and mescaline in general are currently underrepresented in the psychedelic medicine sector, given their traditional medicinal uses. Lophos provides a critically important sustainable supply of cacti to the market. We plan to utilize our expertise in natural health products to aid Lophos in bringing to market, innovative and safe products for the Canadian consumer,” added Najla Guthrie, President and CEO of KGK. ABOUT LOPHOS Lophos Pharmaceuticals Inc. is a biosciences company that specializes in Peyote research, cultivation, preservation, and drug developmen...